Impact of human papillomavirus vaccination on cervical cytology screening, colposcopy, and treatment

American Journal of Epidemiology

Volumn 178, Issue 5, 2013, Pages 752-760

  Rodríguez, Ana Cecilia ^a   Solomon, Diane ^b   Herrero, Rolando ^a,c   Hildesheim, Allan ^b   González, Paula ^a,c   Wacholder, Sholom ^b   Porras, Carolina ^a   Jiménez, Silvia ^a   Schiffman, Mark ^b   Alfaro, Mario ^a   Barrantes, Manuel ^a   Bratti, M Concepción ^a   Cárdenas, Fernando ^a   Cortés, Bernal ^a   Espinoza, Albert ^a   Estrada, Yenory ^a   Jiménez, Silvia E ^a   Morales, Jorge ^a   Villegas, Luis ^a   Morera, Lidia Ana ^a   Pérez, Elmer ^a   Rivas, Libia ^a   Freer, Enrique ^d   Bonilla, José ^d   García Piñeres, Alfonso ^d   Silva, Sandra ^d   Atmella, Ivannia ^d   Ramírez, Margarita ^d   Kreimer, Aimée R ^b   Lowy, Douglas R ^b   Macklin, Nora ^b   Schiller, John T ^b   Sherman, Mark ^b   Pinto, Ligia ^e   Kemp, Troy ^e   Eklund, Claire ^f   Hutchinson, Martha ^f   Sidawy, Mary ^g   Quint, Wim ^h   Van Doorn, Leen Jan ^h   more..

^a Guanacaste Epidemiology Project   (Costa Rica)

^b NATIONAL CANCER INSTITUTE   (United States)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d UNIVERSIDAD DE COSTA RICA   (Costa Rica)

^e SAIC FREDERICK INC   (United States)

^f WOMEN AND INFANTS HOSPITAL   (United States)

^g GEORGETOWN UNIVERSITY   (United States)

^h Delft Diagnostic Laboratory   (Netherlands)

Author keywords

cervical cancer; HPV; HPV vaccination; human papillomavirus; screening

Indexed keywords

HEPATITIS A VACCINE; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE;

ADULT; CANCER; CYTOLOGY; DISEASE TREATMENT; HEALTH SERVICES; HEPATITIS; PUBLIC HEALTH; VACCINATION;

ADULT; ARTICLE; COHORT ANALYSIS; COLPOSCOPY; CONTROLLED STUDY; COSTA RICA; FEMALE; HEPATITIS A; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMAVIRUS INFECTION; PATIENT REFERRAL; SCREENING TEST; UTERINE CERVIX CYTOLOGY; VACCINATION; WART VIRUS;

CERVICAL CANCER; HPV; HPV VACCINATION; HUMAN PAPILLOMAVIRUS; SCREENING;

COLPOSCOPY; EARLY DETECTION OF CANCER; FEMALE; HEPATITIS A VACCINES; HUMANS; PAPILLOMAVIRUS VACCINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VAGINAL SMEARS;

COSTA RICA;

HUMAN PAPILLOMAVIRUS;

EID: 84883477817     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwt047     Document Type: Article

References (14)

1. Franco EL, Mahmud SM, Tota J, et al. The expected impact of HPV vaccination on the accuracy of cervical cancer screening: The need for a paradigm change. Arch Med Res. 2009; 40(6):478-485
2. Schiffman M. Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer. 2007;111(3):145-153
3. Brotherton JM, Fridman M, May CL, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: An ecological study. Lancet. 2011; 377(9783):2085-2092
4. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-Adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):89-99
5. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPVassociated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325-339
6. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: A randomised, double-blind trial. Lancet. 2009;373(9679):1949-1957
7. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): Final analysis of a double-blind, randomised study in young women. Lancet. 2009; 374(9686):301-314
8. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine. 2008;26(37):4795-4808
9. Safaeian M, Herrero R, Hildesheim A, et al. Comparison of the SPF10-LiPA system to the Hybrid Capture 2 Assay for detection of carcinogenic human papillomavirus genotypes among 5,683 young women in Guanacaste, Costa Rica. J Clin Microbiol. 2007;45(5):1447-1454
10. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin. 2012;62(3):147-172
11. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: Terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114-2119
12. Herrero R, Wacholder S, Rodriguez AC, et al. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: A community-based randomized clinical trial in Guanacaste, Costa Rica. Costa Rica Vaccine Trial Group. Cancer Discov. 2011;1(5):408-419
13. Wheeler CM, Castellsague X, Garland SM, et al. Crossprotective efficacy of HPV-16/18 AS04-Adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012;13(1):100-110
14. Rodriguez AC, Schiffman M, Herrero R, et al. Longitudinal study of human papillomavirus persistence and cervical intraepithelial neoplasia grade 2/3: Critical role of duration of infection. J Natl Cancer Inst. 2010;102(5):315-324